Kala Bio, INC. (KALA) — SEC Filings

Overview

Kala Bio, INC. (KALA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a DEF 14A filed on Dec 30, 2025: KALA BIO, Inc. is holding its 2025 Annual Meeting of Stockholders on January 30, 2026, virtually, to address several critical proposals impacting its corporate structure and financial future. Stockholders will vote on the election of three Class II directors: David Lazar, Mark Iwicki, and Todd Bazem

Sentiment Summary

Across 39 filings, the sentiment breakdown is: 2 bearish, 35 neutral, 2 mixed. The dominant filing sentiment for Kala Bio, INC. is neutral.

Filing Type Overview

Kala Bio, INC. (KALA) has filed 1 DEF 14A, 20 8-K, 6 10-Q, 1 8-K/A, 2 10-K, 2 SC 13G, 2 SC 13D, 2 DEFA14A, 3 SC 13G/A with the SEC between Jan 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (39)

• KALA BIO Seeks Shareholder Nod for Massive Stock Increase, Reverse Split — DEF 14A · Dec 30, 2025 Risk: high
  KALA BIO, Inc. is holding its 2025 Annual Meeting of Stockholders on January 30, 2026, virtually, to address several critical proposals impacting its corporate
• 8-K Filing — 8-K · Dec 29, 2025
• 8-K Filing — 8-K · Dec 16, 2025
• KALA BIO, Inc. Files 8-K for Material Agreement — 8-K · Dec 5, 2025 Risk: medium
  KALA BIO, Inc. filed an 8-K on December 5, 2025, reporting on events that occurred on December 4, 2025. The filing indicates the entry into a material definitiv
• Kala Bio Announces Material Agreements & Equity Sales — 8-K · Nov 25, 2025 Risk: medium
  Kala Bio, Inc. announced on November 20, 2025, the termination of a material definitive agreement and entered into a new material definitive agreement. The comp
• KALA BIO Halts Key Drug Development, Cuts Staff Amid Cash Crunch — 10-Q · Nov 19, 2025 Risk: high
  KALA BIO, Inc. reported a net loss of $27.666 million for the nine months ended September 30, 2025, a slight improvement from the $30.336 million loss in the sa
• 8-K Filing — 8-K · Nov 12, 2025
• KALA BIO, Inc. Reports Material Agreements and Equity Sales — 8-K · Nov 10, 2025 Risk: medium
  KALA BIO, Inc. filed an 8-K on November 10, 2025, reporting on several key events that occurred on November 9, 2025. These include entering into a material defi
• Kala Bio, Inc. Files 8-K on Executive Changes and Restructuring — 8-K · Oct 20, 2025 Risk: medium
  Kala Bio, Inc. filed an 8-K on October 20, 2025, reporting on several events. These include cost associated with exit or disposal activities, departure of direc
• KALA BIO, Inc. Files 8-K/A Amendment — 8-K/A · Oct 2, 2025 Risk: medium
  KALA BIO, Inc. filed an 8-K/A amendment on October 2, 2025, related to events occurring on September 28, 2025. The filing pertains to cost associated with exit
• KALA BIO, Inc. Reports Financial Obligation Triggering Event — 8-K · Oct 1, 2025 Risk: medium
  KALA BIO, Inc. filed an 8-K on October 1, 2025, reporting a triggering event that accelerates or increases a direct financial obligation or an obligation under
• KALA BIO, Inc. Files 8-K on Exit Activities — 8-K · Sep 29, 2025 Risk: medium
  KALA BIO, Inc. filed an 8-K on September 29, 2025, reporting on events as of September 28, 2025. The filing indicates costs associated with exit or disposal act
• KALA BIO, Inc. Files 8-K on Shareholder Nominations — 8-K · Sep 18, 2025 Risk: medium
  KALA BIO, Inc. filed an 8-K on September 18, 2025, reporting events as of September 16, 2025. The filing pertains to Shareholder Nominations Pursuant to Exchang
• KALA BIO, Inc. Files 8-K on Executive Changes and Financials — 8-K · Sep 2, 2025 Risk: low
  KALA BIO, Inc. filed an 8-K on August 29, 2025, reporting on the departure of directors or certain officers, the election of directors, the appointment of certa
• KALA BIO Narrows Q2 Loss Amidst Continued Equity Raises — 10-Q · Aug 8, 2025 Risk: high
  KALA BIO, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with the prior year periods. The company's net loss for the thre
• KALA BIO, Inc. Files 8-K — 8-K · Jul 9, 2025 Risk: low
  KALA BIO, Inc. filed an 8-K on July 9, 2025, reporting an "Other Event." The filing does not contain specific details about the event itself, but it confirms th
• Kala Bio Q1 Loss Narrows, Cash Reserves Stand at $51.25M — 10-Q · May 14, 2025 Risk: medium
  Kala Bio, Inc. reported its first quarter 2025 results for the period ending March 31, 2025. The company's financial statements show a net loss of $6.41 million
• Kala Bio Announces Board and Executive Compensation Changes — 8-K · Apr 11, 2025 Risk: medium
  Kala Bio, Inc. announced on April 10, 2025, changes in its board of directors and executive compensation arrangements. The filing details the departure of certa
• Kala Bio Files 2024 10-K, Details Securities Purchase Agreements — 10-K · Mar 31, 2025 Risk: medium
  Kala Bio, Inc. filed its 10-K for the fiscal year ending December 31, 2024. The company reported significant financial activities, including a Third Securities
• Kala Bio Announces Board and Executive Changes — 8-K · Feb 12, 2025 Risk: medium
  KALA BIO, Inc. announced on February 11, 2025, changes in its board of directors and executive compensation arrangements. The filing details the departure of ce
• Kala Bio Files 8-K: Material Agreement, Equity Sales, Bylaw Changes — 8-K · Dec 30, 2024 Risk: medium
  Kala Bio, Inc. filed an 8-K on December 30, 2024, reporting events as of December 29, 2024. The filing indicates an entry into a material definitive agreement,
• SC 13G Filing — SC 13G · Nov 14, 2024
• Kala Bio Q3 2024: $275.9M Assets, $4.6M Cash — 10-Q · Nov 12, 2024 Risk: medium
  Kala Bio, Inc. reported its third quarter 2024 results, with total assets reaching $275.9 million as of September 30, 2024. The company's cash and cash equivale
• Kala Bio Announces CMO Departure, New Directors — 8-K · Sep 25, 2024 Risk: medium
  Kala Bio, Inc. announced on September 23, 2024, the departure of its Chief Medical Officer, Dr. Marcus Magnus, effective September 20, 2024. The company also ap
• Kala Bio Q2 2024: Assets $276M, Liabilities $4.6M — 10-Q · Aug 6, 2024 Risk: medium
  Kala Bio, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported total assets of $275,937,200 and total liabilities of $4,598,419. Signif
• SR One Capital Management Discloses Stake in Kala Bio — SC 13D · Jul 8, 2024 Risk: medium
  SR One Capital Management, LLC, along with affiliated entities Simeon George and SR One Capital Fund II Aggregator, LP, has filed a Schedule 13D on July 8, 2024
• Baker Bros. Advisors reports 17.1% stake in KALA BIO, Inc. — SC 13D · Jun 28, 2024 Risk: medium
  Baker Bros. Advisors LP, along with its general partner and principals Felix J. Baker and Julian C. Baker, reported a beneficial ownership of 10,000,000 shares
• Kala Bio Announces Material Agreement and Equity Transactions — 8-K · Jun 27, 2024 Risk: medium
  Kala Bio, Inc. announced on June 26, 2024, that it entered into a material definitive agreement. The company also reported on unregistered sales of equity secur
• KALA BIO Files 8-K on Shareholder Vote Matters — 8-K · Jun 12, 2024 Risk: low
  KALA BIO, Inc. filed an 8-K on June 12, 2024, reporting on a submission of matters to a vote of security holders that occurred on June 11, 2024. The company, fo
• KALA BIO Proxy Statement Filed — DEFA14A · May 30, 2024 Risk: low
  KALA BIO, Inc. filed a DEFA14A on May 30, 2024, making available a communication to certain stockholders. This filing is a definitive proxy statement related to
• Kala Bio, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 14, 2024 Risk:
  KALA BIO, Inc. (KALA) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. Kala Bio, Inc. reported $0 in revenue for the quarter ended March 31, 2024.
• Kala Bio Files Proxy Materials — DEFA14A · Apr 29, 2024 Risk: low
  Kala Bio, Inc. filed a Definitive Additional Materials (DEFA14A) on April 29, 2024. This filing relates to the company's proxy statement and indicates no fee wa
• KALA BIO, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 29, 2024 Risk: medium
  KALA BIO, Inc. (KALA) filed a Annual Report (10-K) with the SEC on March 29, 2024. KALA BIO, Inc. (KALA) filed its 2023 Form 10-K on March 29, 2024. The company
• KALA BIO, Inc. Files 8-K: Material Agreement & Equity Sales — 8-K · Mar 26, 2024 Risk: medium
  KALA BIO, Inc. announced on March 25, 2024, that it entered into a Material Definitive Agreement. The company also reported on unregistered sales of equity secu
• Bausch + Lomb to Acquire KALA BIO, Inc. — 8-K · Mar 4, 2024 Risk: medium
  KALA BIO, Inc. announced on March 4, 2024, that it has entered into a definitive agreement to be acquired by a subsidiary of Bausch + Lomb Corporation. The tran
• SC 13G Filing — SC 13G · Feb 16, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• Millennium Management Reduces KALA BIO Stake as of Dec 31, 2023 — SC 13G/A · Jan 29, 2024
  Millennium Management LLC, through its affiliates Integrated Core Strategies (US) LLC and Millennium Group Management LLC, has updated its ownership stake in KA

Risk Profile

Risk Assessment: Of KALA's 30 recent filings, 3 were flagged as high-risk, 22 as medium-risk, and 5 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Kala Bio, INC.'s most recent 10-Q filing (Nov 19, 2025):

• Revenue: N/A
• Net Income: -$27.666M
• EPS: -$1.07
• Debt-to-Equity: N/A
• Cash Position: $21.096M
• Operating Margin: N/A
• Total Assets: $25.021M
• Total Debt: $29.523M

Key Executives

• David Lazar
• Mark Iwicki
• Todd Bazemore
• Dr. Marcus Magnus
• Dr. Michael Heffernan
• Ms. Sarah Kelly
• Mr. David Epstein
• Simeon George
• Sasha Keough
• Felix J. Baker
• Julian C. Baker

Industry Context

KALA BIO operates in the biotechnology sector, a highly competitive and capital-intensive industry. Companies in this space often face significant R&D costs, lengthy development cycles, and stringent regulatory hurdles. Success hinges on innovation, clinical trial outcomes, and the ability to secure funding for ongoing operations and pipeline development.

Top Tags

material-agreement (6) · biotech (6) · equity-sale (5) · corporate-governance (5) · corporate-action (4) · 10-Q (4) · financial-obligation (3) · filing (3) · financials (3) · Biotechnology (2)

Key Numbers

• Proposed Authorized Common Stock: 1,500,000,000 — Significant increase from current authorized shares, indicating potential for future dilution.
• Minimum Reverse Stock Split Ratio: 1-for-2 — Part of a range (1-for-2 to 1-for-100) to be determined by the board, aimed at increasing per-share price.
• Maximum Reverse Stock Split Ratio: 1-for-100 — Part of a range (1-for-2 to 1-for-100) to be determined by the board, aimed at increasing per-share price.
• Shares of Common Stock Outstanding: 23,249,725 — As of the record date, December 30, 2025, entitled to vote at the annual meeting.
• Record Date: 2025-12-30T00:00:00.000Z — Date for determining stockholders entitled to vote at the annual meeting.
• Annual Meeting Date: 2026-01-30T00:00:00.000Z — Date of the virtual 2025 Annual Meeting of Stockholders.
• Cash and cash equivalents: $21.096M — Decreased from $51.181M at Dec 31, 2024, indicating significant cash burn.
• Net loss: $27.666M — For the nine months ended Sept 30, 2025, showing continued unprofitability.
• Current portion of long-term debt: $28.411M — Increased from $10.336M at Dec 31, 2024, posing a significant short-term liquidity challenge.
• Total stockholders' (deficit) equity: $(8.665)M — Shifted from $12.332M equity at Dec 31, 2024, indicating negative shareholder value.
• Net cash used in operating activities: $27.435M — For the nine months ended Sept 30, 2025, highlighting operational cash drain.
• Net loss per share (Q3 2025): $1.07 — Compared to $1.93 in Q3 2024, showing a smaller loss per share despite operational challenges.
• Common shares outstanding: 7,432,925 — As of Sept 30, 2025, up from 6,091,182 at Dec 31, 2024, indicating dilution.
• Workforce reduction costs: $378K — Incurred during Q3 2025, primarily severance and benefits.
• Revenue: $0 — No revenue for Q2 2025 or H1 2025, consistent with prior periods.

Related Companies

BHC

Frequently Asked Questions